Posted by Michael Wonder on 20 Mar 2025
Health Canada approves Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy
19 March 2025 - Approval is based on the Phase 3 KEYNOTE-868/NRG-GY018 trial.
Merck announced today that Health Canada approved Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
